Pharmala Biotech Holdings Inc. (MDMA.CN)

CAD 0.23

(-4.17%)

Market Cap (In CAD)

22.06 Million

Revenue (In CAD)

532 Thousand

Net Income (In CAD)

-779.81 Thousand

Avg. Volume

188.02 Thousand

Currency
CAD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.065-0.35
PE
-
EPS
-
Beta Value
1.23705
ISIN
CA71719L1067
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Nicholas Kadysh
Employee Count
-
Website
https://pharmala.ca
Ipo Date
2022-01-11
Details
Pharmala Biotech Holdings Inc., doing business as PharmAla, focuses on the developing, manufacturing, and commercializing of substituted methylenedioxy-phenethylamines (MDXX) active pharmaceutical ingredients. It also provides MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB); and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), as well as formulations of MDXX compounds. The company is headquartered in Vancouver, Canada.